Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage
Precigen (PGEN) reported a significant financial turnaround in Q2 2026, achieving profitability with $54.98 million in revenue and $20.07 million in net income, driven by the strong uptake of its drug Papsimios. This success is supported by broad payer coverage for 315 million US lives and a seven-year FDA market exclusivity for adult recurrent respiratory papillomatosis. While this strengthens Precigen's near-term outlook, the company's long-term growth and liquidity still depend on sustained demand for Papsimios and managing its fixed costs.
Precigen (PGEN) Insider Rutul Shah Sells 32,739 Shares
Precigen (PGEN) insider Rutul Shah sold 32,739 shares of the company on August 6, 2026, totaling approximately $224,589. This transaction is part of a larger pattern where insiders have sold significantly more shares than they purchased over the past year. Despite the stock trading at a substantial discount to its GF Value, GuruFocus has labeled it a "Possible Value Trap," advising caution due to potential underlying concerns.
COO sale: Precigen (PGEN) insider trades 32,739 shares via plan
Precigen's Chief Operating Officer, Rutul R Shah, sold 32,739 shares of common stock at $6.86 per share on August 6, 2026, through a Rule 10b5-1 trading plan. Following this transaction, Shah directly holds 465,012 shares. The sale amounted to approximately $225,000, and the filing indicates it was an open-market or private transaction.
PRECIGEN, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $14
H.C. Wainwright has raised its target price for Precigen, Inc. to $18, an increase from its previous target of $14. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance.
Results: Precigen, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
The article discusses how Precigen, Inc. exceeded expectations, leading analysts to update their financial estimates for the company. This suggests a positive outlook for Precigen's future performance based on recent results.
Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage
Precigen (PGEN) reported a significant return to profitability in Q2 2026, driven by strong revenue and net income largely attributed to the rapid uptake of Papsimios. The company's profitability and broad payer coverage, along with seven-year FDA market exclusivity for Papsimios, strengthen its investment narrative. Future growth and liquidity, however, will depend on sustained real-world usage and pricing evolution of the product.
Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale
Precigen, Inc. has filed a Form 144 notice for the sale of 32,739 common shares with an aggregate value of $224,589.54 through Fidelity Brokerage Services LLC on NASDAQ. These shares were originally acquired through restricted stock vesting as compensation on three different dates between 2020 and 2022. The filing also notes a total of 358,035,247 related common securities.
Precigen (PGEN) Stock Rallies As PAPZIMEOS Delivers First Clean Profit
Precigen (PGEN) stock rallied 5.5% after the company reported its first profitable quarter, driven by strong sales of its new therapy, PAPZIMEOS, for recurrent respiratory papillomatosis. Q2 revenue reached US$55 million, with PAPZIMEOS contributing US$53.1 million, resulting in a net income of US$20.1 million. While the company's profitability is a positive sign, questions remain about the sustainability of its single-product focus and the long-term durability of PAPZIMEOS demand.
Germantown biopharma Precigen turns first quarterly profit after key drug scores FDA approval
Germantown-based biopharma company Precigen Inc. has reported its first quarterly profit. This achievement comes a year after its immunotherapy drug received FDA approval, with sales of the drug being the main driver of the profit.
PRECIGEN, INC. 2026: Revenue $54.98M, EPS $0.05— 10-Q Summary
PRECIGEN, INC. (PGEN) reported strong results for the quarter ending 2026, with revenue reaching $54.98 million and diluted EPS at $0.05, significantly improving from the prior year. This growth was primarily driven by the successful commercial launch of Papzimeos, following its FDA approval in August 2025. The company shifted its focus from R&D to commercialization, increasing marketing efforts to support market adoption of its new product.
Precigen Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
HC Wainwright & Co. has reiterated its Buy rating for Precigen, maintaining a price target of $14.00 per share. This indicates continued analyst confidence in the company's stock performance.
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen, Inc. has released its earnings summary for the quarter that concluded on June 30. The article is from Refinitiv and is hosted on TradingView, which also offers access to news from Reuters and other sources.
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
Precigen announced strong second-quarter 2026 financial results, driven by accelerating revenue growth from its drug PAPZIMEOS, which generated $53.1 million in net revenue and led the company to profitability. The company reported that PAPZIMEOS has achieved broad U.S. adoption and payer coverage, secured a permanent J-code for reimbursement, and was granted seven-year market exclusivity by the FDA. Precigen anticipates reaching cash flow break-even by the end of 2026, supported by PAPZIMEOS sales, and is also advancing PRGN-2009 for HPV-associated cancers.
Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates
Precigen, Inc. (PGEN) reported Q2 earnings of $0.05 per share, significantly surpassing the Zacks Consensus Estimate of a $0.02 loss, and revenues of $54.98 million, exceeding expectations by 97.62%. The company has outperformed the S&P 500 this year with a 58.1% gain, and currently holds a Zacks Rank #3 (Hold).
Precigen earnings set to test gene therapy growth trajectory
Precigen Inc. is set to announce its second-quarter results, with investors keenly watching for continued revenue growth from its PAPZIMEOS gene therapy launch and progress towards profitability. Analysts anticipate a loss of $0.01 per share on $27.83 million in revenue, driven by strong market uptake of PAPZIMEOS. The company's commercial execution, cash position, and pipeline developments, particularly for PRGN-2009, will be key areas of focus.
Precigen COO Rutul Shah sells $219,518 in company stock
Precigen's COO, Rutul R. Shah, sold 33,772 shares of common stock for $219,518 at $6.50 per share on August 3, 2026, while simultaneously acquiring the same number of shares for $78,688 through stock option exercise. Following these transactions, Shah holds 497,751 direct shares and 123,304 derivative securities. This comes as Precigen reported strong Q1 2026 earnings and received orphan drug exclusivity for PAPZIMEOS from the FDA, solidifying its market position.
PGEN (PGEN) shareholder Rutul Shah files to sell 33,772 common shares
Rutul Shah, a shareholder of Precigen, Inc. (PGEN), has filed a Form 144 to sell 33,772 common shares. The proposed sale, valued at $219,518.00, will occur on or after August 3, 2026, via Fidelity Brokerage Services LLC on NASDAQ. These shares were acquired through a stock option exercise, and the filing also reports a prior sale of 42,924 common shares on June 29, 2026.
Precigen, Inc. Revenue Breakdown – NASDAQ:PGEN
Precigen, Inc. (NASDAQ:PGEN) reported total revenue of $9.68 million USD last year. The majority of this revenue, $4.45 million USD, was generated from its top-performing segment, Exemplar. The United States was the primary geographic contributor, accounting for the entire $9.68 million USD in revenue.
Precigen Insider Sold Shares Worth $606,000, According to a Recent SEC Filing
An insider at Precigen, Inc. sold shares valued at $606,000, as reported in a recent SEC filing. This transaction follows other recent insider share sales by the company, including sales worth $1,113,143 and $2,042,864 in early July. Precigen is a biopharmaceutical company focused on developing gene and cell therapies for various medical needs, including immuno-oncology and autoimmune disorders.
Precigen (NASDAQ: PGEN) CFO sells 100,000 shares in 10b5-1 plan
Precigen's Chief Financial Officer, Harry Thomasian Jr., sold 100,000 shares of common stock on July 31, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $6.06, totaling approximately $606,000. Following this transaction, Thomasian Jr. directly holds 254,535 shares of Precigen common stock.
PGEN (PGEN) insider outlines planned sale of 100,000 common shares
Harry Thomasian Jr., an insider at Precigen, Inc. (PGEN), has announced plans to sell 100,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $605,609.66. These shares are related to restricted stock vesting on August 28, 2024. This filing follows previous sales by Thomasian Jr. in June and July 2026.
Precigen Inc (PGEN) Institutional Confidence
Precigen Inc's institutional confidence score is 7.00, ranking 50th out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion increased by 12.24% quarter-over-quarter, reaching 75.82%. Steven Cohen is the largest institutional shareholder, holding 5.84 million shares, representing 1.87% of shares outstanding.
PGEN|Precigen Inc|Price:5.950|Chg%:+0.500
TradingKey provides a comprehensive stock analysis of Precigen Inc (PGEN), highlighting its stable fundamentals, high growth potential, and fair valuation. The company's revenue has grown significantly, and it boasts high institutional ownership, with multiple analysts rating it a "Buy." Despite some technical indicators suggesting a sideways trend, the overall outlook for the stock is positive in the medium term.
Earnings Preview: Precigen to Report Financial Results Post-market on August 04
This article announces that Precigen (PGEN) is scheduled to report its financial results after market close on August 4, 2026. The report will cover the company's performance and is an anticipated event for investors and analysts following the company.
PGEN|Precigen Inc|Price:5.425|Chg%:+0.025
This article provides a detailed company profile for Precigen Inc (PGEN), a biopharmaceutical company specializing in gene and cell therapies. It covers the company's background, business scope, financial data, and market performance, including executive leadership and major shareholders. Key information such as market capitalization, an overview of its segments (Biopharmaceuticals and Exemplar), and top revenue sources are also provided.
Precigen Inc (PGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Precigen Inc (PGEN) regarding its dividend history and stock splits. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents basic stock information like its current price ($5.640), daily change (+4.44%), and market capitalization ($2.00B).
Precigen Inc Revenue Breakdown – DUS:I5X
Precigen Inc (DUS:I5X) generated 8.25 million EUR in revenue last year. Its top-performing segment, Exemplar, contributed 3.79 million EUR, which was consistent with the previous year. The United States was the primary revenue source, accounting for the entire 8.25 million EUR.
Precigen Inc Revenue Breakdown – GETTEX:I5X
This article provides a revenue breakdown for Precigen Inc (GETTEX:I5X), detailing its top-performing segment and geographical contributions. Last year, the company generated 8.25M EUR, with the Exemplar segment contributing 3.79M EUR and the United States accounting for all of the revenue.
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen, Inc. (Nasdaq: PGEN) will release its full-year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The biopharmaceutical company will host a conference call on the same day at 4:30 PM ET to discuss the results. Precigen specializes in developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The company will host a conference call on the same day at 4:30 PM ET to discuss these results. Interested parties can access event details on Precigen's investor relations website.
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The company will host a conference call at 4:30 PM ET on that day to discuss the results. Precigen is a commercial-stage biopharmaceutical company focused on innovative precision medicines for difficult-to-treat diseases.
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The company will host a conference call at 4:30 PM ET on that day to discuss the results. Precigen specializes in developing precision medicines for difficult-to-treat diseases, including immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress
Precigen (PGEN) will announce its Q2 financial results on August 4, 2026, and hold a conference call to discuss business developments, including the recent FDA approval of PAPZIMEOS. The company reported a significant revenue increase in Q1 2026 due to PAPZIMEOS sales, leading to a GF Value™ suggesting the stock is 11.2% undervalued. However, the company faces challenges in financial strength and profitability, and insider selling activity raises caution for investors.
Precigen sets 4:30 p.m. ET call for Aug. 4 business update
Precigen (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. A conference call to discuss the results will be held at 4:30 PM ET, and details are available on the company’s investor website. The article also notes recent insider selling activity for the stock.
ETFs Investing in Precigen Inc Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold shares of Precigen Inc. (PGEN), detailing each fund's market value, Precigen Inc. stock weight, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs cover various investment strategies including passive, active, small-cap, health care, and biotech, offering investors different avenues to gain exposure to Precigen Inc.
Precigen (PGEN) Proxy Filing Summary
Precigen's upcoming annual meeting on June 26, 2025, will address director elections, an increase in authorized common stock, approval of Series A Preferred Stock and Warrants issuance to Randal J. Kirk, auditor ratification, executive compensation, and amendments to equity incentive plans. The Board recommends voting for all proposals, with Mr. Kirk abstaining on his PIK dividends proposal. Voting details for shareholders of record as of April 25, 2025, are provided, along with information on future shareholder proposal and director nomination deadlines.
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
Precigen CFO Harry Thomasian Jr. sold 200,000 shares for $1.1 million, reducing his direct ownership by 36% through a pre-arranged Rule 10b5-1 trading plan. This sale, occurring when shares hit a multi-year high, is not considered a red flag for investors due to the non-discretionary nature of the transaction. The company recently reported strong Q1 revenue and its Papzimeos treatment received orphan drug status from the FDA.
Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative
Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driven by the rapid uptake of its PAPZIMEOS treatment. However, its high P/B ratio of 98x compared to an industry average of 2.8x raises concerns about potential valuation risk, especially for a company that is still loss-making.
PGEN - Precigen Inc Options
This article provides a detailed financial overview of Precigen Inc (PGEN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, such as EPS, sales growth, insider and institutional ownership, and stock performance over different periods. The data indicates significant year-over-year sales growth but negative income and profitability metrics.
[144] PRECIGEN, INC. SEC Filing
This article announces an SEC Form 144 filing by Precigen, Inc. (PGEN), detailing a proposed sale of securities. The filing indicates a sale of 346,836 shares of common stock with an aggregate market value of $2,044,627.16 by an individual named Smithfield, acquired through a stock option exercise on June 29, 2026, and to be sold on NASDAQ via Fidelity Brokerage Services LLC. The document provides details on the filer, issuer, and securities information as required by the SEC.
Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at Precigen sold shares totaling $1,113,143. This information is derived from the latest regulatory disclosure, indicating a significant insider transaction for the company.
PGEN - Precigen Inc Latest SEC Filings
This article provides the latest SEC filings for Precigen Inc (PGEN), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It details current market capitalization, income, sales, EPS, and various valuation ratios, alongside recent perfromance over different periods, offering a comprehensive snapshot of the company's financial health and market standing.
[Form 4] PRECIGEN, INC. Insider Trading Activity
PRECIGEN, INC.'s President and CEO, Helen Sabzevari, conducted an exercise-and-sale transaction on June 29, 2026. She acquired 346,836 shares through stock options at $2.33 per share and subsequently sold them in open-market transactions at a weighted average price of $5.89, under a Rule 10b5-1 trading plan. After these transactions, her direct ownership includes 3,768,872 shares of common stock and 500,164 stock options, indicating the sale was a small portion of her overall equity.
Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan
Precigen's Chief Financial Officer, Harry Thomasian Jr., sold a total of 200,000 shares of Common Stock in open-market transactions on June 29 and July 1, 2026, under a pre-arranged 10b5-1 trading plan. The sales were executed at weighted average prices of $5.78 and $5.53 per share, respectively, totaling over $1.11 million. After these sales, Mr. Thomasian Jr. directly holds 354,535 Common Stock shares in Precigen (PGEN).
Precigen (PGEN) COO sells 42,924 shares after option exercise
Precigen's Chief Operating Officer, Rutul R. Shah, exercised stock options to acquire 42,924 shares at $2.33 per share and subsequently sold all those shares in an open-market transaction at $5.85 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Shah directly holds 497,751 shares and retains options for an additional 157,076 shares.
Does Precigen’s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story?
Precigen (PGEN) was removed from several Russell value indexes on June 27, 2026, which may lead to portfolio rebalancing by passive funds and shift its investor base towards more active investors. The company's investment narrative centers on the success of PAPZIMEOS and its ability to scale, with a recent FDA approval providing clinical and regulatory validation. Despite a projected significant increase in revenue and a high fair value estimate, there are wide discrepancies in analyst fair value estimates, underscoring the importance of monitoring execution milestones and funding needs.
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark
Precigen, Inc. (PGEN) has been removed from the Russell 2000 Value Benchmark. This news follows a series of recent updates for the biopharmaceutical company, including winning FDA Orphan Drug Exclusivity for an airway disease treatment and reporting Q1 2026 earnings. The company, which focuses on gene and cell therapies, also saw its shares drop by 1.62%.
[144] PRECIGEN, INC. SEC Filing
This article reports on a Form 144 SEC filing by Precigen, Inc. (PGEN). The filing indicates a proposed sale of 28,571 shares of common stock with an aggregate market value of $165,196.70 on June 29, 2026, through Fidelity Brokerage Services LLC. The shares were acquired via an open market purchase on January 25, 2023.
Precigen Inc Actuals & Estimates (BX:I5X)
This article provides an overview of Precigen Inc (BX:I5X) financial actuals and estimates, including income statement, balance sheet, and cash flow data, along with analyst forecasts. It covers key financial metrics such as market capitalization, earnings per share, revenue, net income, and EBITDA, and answers frequently asked questions about the company's stock. The next earnings report for Precigen Inc is scheduled for August 10, 2026.
Precigen Shareholders Expand Incentive Plan, Reaffirm Governance
Precigen shareholders approved an amendment to the company's 2023 Omnibus Incentive Plan, adding 7 million shares for equity awards, signaling continued support for equity-based compensation. They also re-elected directors, ratified auditors, and supported executive pay, reaffirming current governance. Despite strong early commercialization momentum for PAPZIMEOS and moderating cash use expectations, TipRanks’ AI Analyst, Spark, rates PGEN as Neutral due to weak financial fundamentals.
